HeartMate II
This article was originally published in The Gray Sheet
Executive Summary
Thoratec will launch the HeartMate II continuous-flow left-ventricular assist device in Europe by the end of the year following receipt of a CE mark Nov. 7. The approval was based on data from 20 patients enrolled in a Phase I U.S. trial and a European trial. A 200-patient Phase II study to support U.S. approval of the next-generation device has enrolled 102 patients so far - 52 in the bridge-to-transplant arm and 50 in the destination-therapy arm. A total of 143 patients have been implanted with HeartMate II to date, according to the firm...
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.